Related Experiment Videos
Early detection of myocardial dysfunction and heart failure
Geoffrey de Couto1, Maral Ouzounian, Peter P Liu
1Toronto General Hospital, University Health Network, NCSB 11-1266, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada.
Insights
Early detection of cardiac dysfunction is crucial for preventing heart failure progression. Utilizing serological biomarkers and advanced imaging can identify at-risk patients before symptoms manifest, enabling timely interventions.
Area of Science:
- Cardiology
- Biomarker Research
- Medical Imaging
Background:
- Heart failure and cardiac dysfunction are increasing globally.
- Current treatments focus on symptomatic stages, often after irreversible damage.
- Early identification is key to preventing or delaying heart failure onset.
Purpose of the Study:
- To explore strategies for early identification of asymptomatic cardiac dysfunction.
- To evaluate the utility of biomarkers and noninvasive imaging in risk stratification.
- To discuss novel approaches for monitoring myocardial health.
Main Methods:
- Review of existing and emerging serological biomarkers (e.g., B-type natriuretic peptide, troponins, protein ST2).
- Discussion of noninvasive imaging techniques like three-dimensional speckle tracking and PET-CT.
- Proposal of a staged screening approach for patients with risk factors.
Main Results:
- Existing biomarkers like B-type natriuretic peptide and troponins are valuable.
- Novel markers (protein ST2, galectin-3) show potential for incremental prognostic information.
- Advanced imaging can reveal myocardial changes before overt abnormalities.
Conclusions:
- A staged approach using biomarkers and imaging can aid early detection of cardiac dysfunction.
- Novel biomarkers and advanced imaging offer promising insights into preclinical disease.
- Early intervention strategies are essential for managing the rising impact of heart failure.
Abstract:
The impact of cardiac dysfunction and heart failure is continuing to escalate in the developed world. Treatment of this heterogeneous condition has focused on the symptomatic stage, often after irreversible remodeling and functional impairment have occurred. Early identification of cardiac dysfunction would allow implementation of early intervention strategies to delay the progression or to prevent the onset of heart failure altogether. Although screening methods for asymptomatic cardiac dysfunction have yet to be optimized, a staged approach for patients with predisposing risk factors using serological biomarkers followed by noninvasive imaging techniques may be useful. Existing biomarkers for cardiac dysfunction include B-type natriuretic peptide, troponins, and C-reactive protein. Novel markers such as protein ST2, galectin-3, and various prohormones are emerging and may provide prognostic information that is incremental to conventional clinical evaluation. Monitoring myocardial mechanics and molecular processes through three-dimensional speckle tracking and hybrid imaging modalities, such as PET-CT, may provide insight into disease manifestation before overt structural and physiological abnormalities.
Related Concept Videos
Dysrhythmias V: Evaluating Dysrhythmias
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome III: Diagnostic Studies
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiomyopathy III: Hypertrophic Cardiomyopathy